Nursing Considerations for CAR T-Cell Therapy: Management of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome.

Authors

Demi M Miller

Published in

Clinical journal of oncology nursing. Volume 30. Pages E67-E72. Jul 08, 2026.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment for certain hematologic malignancies, but many nurses are not trained in caring for two common side effects, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
This article provides foundational knowledge of CRS and ICANS, including the oncology nurse's role in toxicity monitoring, care coordination, and patient education.
To support safe, evidence-based CAR T-cell therapy administration, this article discusses grading guidelines, nursing assessments, interventions, and education strategies for CRS and ICANS.
Nurses serve a key role in mitigating CRS and ICANS through early recognition, continuous monitoring, therapeutic intervention, and patient and caregiver education. Using standardized protocols, frequently monitoring vital signs, and performing neurologic assessments optimize patient safety and outcomes.

PMID:
42462106
Bibliographic data and abstract were imported from PubMed on 17 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.